Back to top
more

Veracyte (VCYT)

(Real Time Quote from BATS)

$32.27 USD

32.27
242,597

-0.01 (-0.03%)

Updated Sep 17, 2025 01:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Sridatri Sarkar headshot

Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership

by Sridatri Sarkar

TEM accelerates its healthcare edge with Paige, Deep 6 AI, and Ambry Genetics acquisitions, expanding data, tech and clinical reach.

Zacks Equity Research

Is the Options Market Predicting a Spike in Veracyte Stock?

by Zacks Equity Research

Investors need to pay close attention to VCYT stock based on the movements in the options market lately.

Zacks Equity Research

Here's Why Veracyte (VCYT) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Here's Why Veracyte (VCYT) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up

by Zacks Equity Research

Veracyte Q2 earnings and revenues beat estimates, fueled by Decipher and Afirma growth, sending shares up over 15%.

Zacks Equity Research

Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Veracyte (VCYT) delivered earnings and revenue surprises of +41.94% and +7.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Veracyte (VCYT) Soars 7.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Should You Continue to Hold Veracyte Stock in Your Portfolio Now?

by Zacks Equity Research

VCYT's Decipher growth and strong cash position bolster its outlook, but Biopharma headwinds and macro risks loom.

Sridatri Sarkar headshot

Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches

by Sridatri Sarkar

TEM expands its precision medicine arsenal with AI-powered tools, liquid biopsy tech and genome sequencing.

Zacks Equity Research

Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?

by Zacks Equity Research

Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.

Zacks Equity Research

Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up

by Zacks Equity Research

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.

Zacks Equity Research

What Makes Veracyte (VCYT) a New Buy Stock

by Zacks Equity Research

Veracyte (VCYT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veracyte (VCYT) delivered earnings and revenue surprises of 55% and 3.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ekso Bionics (EKSO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -9.09% and 28.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should You Continue to Hold Veracyte Stock in Your Portfolio?

by Zacks Equity Research

Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.

Zacks Equity Research

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

International Growth Drives GMED Stock Amid Fierce Competition

by Zacks Equity Research

Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Zacks Equity Research

Here's Why Veracyte (VCYT) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Bruker Stock May Benefit Following Its Investment in Ridom GmbH

by Zacks Equity Research

BRKR announces a new partnership with NGS bioinformatics solution provider Ridom GmbH.

Zacks Equity Research

Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?

by Zacks Equity Research

BRKR's latest innovation offers 1H NMR and a choice of 15 X-nuclei with just one click.

Zacks Equity Research

Veracyte (VCYT) Just Overtook the 20-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Zacks Equity Research

Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?

by Zacks Equity Research

Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.